Compare GSK plc (GSK) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? GSK plc trades at $50.25 (market cap $102.60B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.39. The key difference: GSK plc pays a 3.57% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and GSK plc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| GSK | YMAG | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $15.98 |
52-Week Low | $38.96 | $10.76 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
YMAG trades at $11.29, down 2.59% today, with technical indicators showing a bullish overall signal despite mixed oscillators. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.07 to $0.40 per share. Recent news highlights YieldMax's distribution announcements and analysis of the fund's option income strategy performance.
The fund's structured option strategy provides high income potential but faces NAV stability challenges during earnings volatility. Key risks include concentrated exposure to Magnificent Seven stocks and option strategy complexity. Technical support sits at $11-12 levels while the bullish moving average trend suggests potential upside momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
